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Abstract
Background: Prostate cancer (PCa) is the most common cancer affecting men in the United States. The initial
treatment and subsequent monitoring of PCa patients places a large burden on U.S. health care systems. The
objectives of this study were to estimate the total and disease-related per-patient lifetime costs using a phase-
based model of cancer care for PCa patients enrolled in Medicare.
Methods: A model was developed to estimate life-time costs for patients diagnosed with PCa. Patients ≥ 65 years
old and diagnosed with PCa between calendar years 1991-2002 were selected from the SEER database. Using SEER,
we estimated survival times for PCa patients from diagnosis until death. The period of time patients contributed to
treatment phases was determined using an algorithm designed to model the natural history of PCa. Costs were
obtained from the US SEER-Medicare database and estimated during specific phases of care. Cost estimates were
then combined with survival data to yield total and PCa-related life-time costs.
Results: Overall, the model estimated life-time costs of $110,520 (95% CI 110,324-110,739) per patient. PCa-related
costs made up approximately 31% of total costs ($34,432).
Conclusions: Prostate cancer places a significant burden on U.S. health-care systems with average life-time PCa-
related costs in excess of $30,000.
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Background
According to the National Cancer Institute’s Surveillance
Epidemiology and End Results (SEER) database, prostate
cancer (PCa) prevalence in 2008 was estimated at
2,555,936 [1]. Prostate cancer is the most common can-
cer affecting men in the United States (U.S.) [1]. This is a
result of both advances in screening following introduc-
tion of the prostate specific antigen (PSA) test as well as
increases in survival attributable to more effective thera-
pies [2]. Although incidence has leveled off in recent
years, the American Cancer Society estimates that
approximately 186,000 men were diagnosed with PCa in
2008 [2]. Approximately 60% of incident prostate cancer
cases are diagnosed at ≥ 65 years of age [3]. The initial
treatment and subsequent monitoring of these large
numbers of PCa cases places a burden on U.S. health
care systems. Prevalence based treatment costs for 2006
alone have been estimated at $9.6 billion [4].
Two therapies including finasteride and dutasteride have
recently been studied for the prevention of PCa [5,6]. Eco-
nomic burden of illness studies are important because
they quantify the costs that could be avoided should these
pharmacologic agents prove effective in reducing incident
cancer cases. Common approaches to estimating disease-
related costs often include the use of a healthcare claims
database. However, databases often do not provide enough
years of follow-up to estimate life-time costs. This is parti-
cularly problematic for PCa as five-year survival rates
approach 100% and censored cost data become a concern
[1]. Thus, there is a paucity of data concerning life-time
PCa costs. This study provides estimates of total and dis-
ease-related per-patient lifetime costs using a phase-based
model of cancer care among patients diagnosed with pros-
tate cancer at ≥ 65 years of age.
Methods
Model Overview
We developed a phase-based model utilizing similar
methodology as a prior study and applied it to PCa in
order to estimate life-time total and disease-related costs
for patients diagnosed with PCa [7]. Using survival data
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from diagnosis until death. The period of time that
patients contributed to clinically relevant phases of treat-
ment (initial, continuing, and terminal care) was then
determined using an algorithm designed to model the
natural history of PCa [7]. Finally, phase-specific monthly
costs were combined with data on the number of months
that patients were alive during each phase of care to yield
total and PCa-related life-time costs. Analyses were con-
ducted from a Medicare payer perspective.
Patient Population
Survival following PCa diagnosis was estimated using data
from the SEER program. At the time of analyses, SEER
was collecting data on cancer incidence, survival, and pre-
valence from specific geographic areas representing
approximately 26% of the U. S .p o p u l a t i o n[ 8 ] .M a l e
patients ≥ 65 years old with a first primary diagnosis of
PCa between January 1, 1991 and December 31, 2002
were selected for inclusion from SEER using the cancer
site recode variable. Patients were excluded if their cancer
stage at diagnosis could not be identified or was Stage 0.
Estimation of Survival and Length of Treatment Phases
Survival data from SEER were used to develop a statistical
model designed to predict life expectancy for patients with
Stage IV PCa. Time to death was calculated as the number
of months between the date of index PCa diagnosis and
the date of death or end of follow-up. Patients were cen-
sored if they were alive at the end of follow-up. Various
parametric distributions including the exponential, Wei-
bull, log-normal, and log-logistic were fitted to the data.
Models were created with time to death as the response
variable and continuous age as the independent variable.
The log-normal distribution was chosen after comparing
-2log-likelihood statistics for each model and comparing
the median observed and predicted survival times to deter-
mine the best fitting distribution. Continuous age was
included as a predictor in the models. A predictive equa-
tion was then derived from the model to estimate life
expectancy for each Stage IV patient according to their
age at diagnosis.
The majority of Stage I-III patients were still alive as of
the last date survival data were collected in SEER. There-
fore, it was not feasible to create a valid model to predict
survival for these patients. For patients with no recorded
date of death, we assumed survival was comparable to
the U.S. general population. This was a conservative
assumption based on a study by Brenner and Arndt
which estimated relative survival rates for localized/regio-
nal PCa that were above 100%a sc o m p a r e dt ot h eg e n -
eral population [9]. Data from U.S. life tables based on
age-specific 2004 death rates were used to estimate survi-
val according to age and race [10].
Following estimation of survival, the time period from
diagnosis until death was divided into distinct phases of
care (initial, continuing, and terminal) using an approach
similar to prior studies [7,11] For patients surviving ≥ 18
months, the initial phase was defined as the first 6
months following prostate cancer diagnosis, the terminal
phase as the last 12 months prior to death, and the conti-
nuing care phase as the time in months between initial
and terminal phases. For patients surviving < 18 months,
the final 12 months of follow-up were allocated first to
the terminal phase and the remaining months were
defined as initial phase.
Estimation of Monthly Treatment Phase Costs
Medicare payment data from the SEER-Medicare data-
base was used to estimate monthly phase-specific total
and disease-related medical costs [12]. Cost data were
estimated from Medicare claims data spanning calendar
years 1991 through 2004 for PCa cases diagnosed
between January 1, 1991 and December 31, 2002 and
were standardized to 2004 U.S. dollars. The main initial
therapeutic options including prostatectomy, radiation,
and hormone therapy were in use during the study peri-
ods over which Medicare costs were estimated. Moni-
toring for cancer recurrence with prostate specific
antigen was also in practice.
Monthly treatment phase total and PCa-related costs
that were input into the model are depicted in Table 1.
PCa-related costs were estimated from the SEER-Medicare
data using a sample of male patients from a random 5%
sample of Medicare beneficiaries without cancer, matched
to PCa cases on 5-year age groups. This non-cancer
cohort was used to estimate the background medical costs
unrelated to PCa. The incremental differences in the aver-
age monthly treatment phase costs between PCa patients
and the cohort without cancer were defined as PCa-related
costs.
Table 1 Mean Monthly Cost Estimates, by Stage and
Treatment Phase for PCa Patients
Study Measure Treatment Phase
Initial Care Continuing Care Terminal Care
Total costs
Stage I $2,058 $693 $3,167
Stage II $2,333 $616 $3,044
Stage III $2,774 $542 $3,056
Stage IV $2,665 $790 $4,315
PCa-related costs
Stage I $1,615 $247 $37
Stage II $1,890 $170 $0
Stage III $2,331 $96 $0
Stage IV $2,212 $344 $1,185
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Phase-specific monthly cost estimates were combined
with survival data from SEER to calculate life-time costs
for patients from diagnosis until death. For each patient,
the corresponding phase-specific monthly cost was mul-
tiplied by the number of months patients contributed to
each treatment phase.
Data Analyses
Baseline demographic and clinical characteristics including
age, race, and geographic region were assessed descrip-
tively by cancer stage for the PCa study cohort used to
estimate survival from diagnosis until death. Life-time
total and PCa-related costs were summarized by cancer
stage. Confidence intervals were calculated around cost
estimates using non-parametric bootstrap methods [13].
The study dataset was re-sampled with replacement to
create 1,000 random samples. Total and prostate cancer-
related costs were then calculated for each of the 1,000
samples. Lower and upper confidence bounds were
obtained from the sample distribution of costs at the 2.5%
and 97.5% quantiles, respectively. Sources of variability
accounted for in the bootstrap include costs according to
treatment phase and cancer stage and the number of
months that patients contribute to each treatment phase.
Life-time total and PCa-related costs were discounted at a
3% annual rate.
Aggregate life-time treatment costs for U.S. incident
PCa cases diagnosed in 2008 and ≥ 65 years of age were
calculated. By combining data from the American Cancer
Society on the number of incident PCa cases (186,620)
diagnosed in 2008 with the proportion of cases ≥ 65 years
of age (60%) from SEER statistics, we estimated the num-
ber of incident cases 65 years of age and older (111,972)
[2,3]. The number of incident cases was then multiplied
by life-time treatment cost estimates in order to calculate
the aggregate total and PCa-related burden of medical
care among patients ≥ 65 years old.
Results
Patient Characteristics
Patient characteristics are shown in Table 2. One-half
(51.1%) of patients were diagnosed at Stage I. Eighteen
percent, 15.7%, and 14.9% wer ed i a g n o s e da tS t a g e sI I ,
III, and IV, respectively. A higher proportion of black
patients were diagnosed at Stage IV (14.0%) compared to
the overall proportion of black patients diagnosed in
Stages I-III (10.0%). The majority of patients (57.4%)
resided in the Western region at the time of PCa diagno-
sis. The predicted survival times from PCa diagnosis until
death varied according to cancer stage (Table 2). Survival
among Stage IV was shorter (Mean: 43.7 months, 3.7
years) versus Stages I-III (Mean: 178.2 months, 14.9
years). Patients diagnosed with Stage III PCa had longer
mean predictive survival times compared to Stages I/II.
The main driver of this result was that Stage III patients
were diagnosed at younger ages (on average 2.3 years
younger) versus Stages I/II (age at diagnosis: 71.3 vs. 73.6
years). The percentage of survival time Stage I-III
patients spent in continuing care was higher (90.4%,
161.1 months) compared to Stage IV (66.8%, 29.2
months).
Total and PCa-related Per-Patient Life-time Costs
Average per-patient total and PCa-related life-time costs
are displayed in Table 3. For all patients, the model esti-
mated average total life-time medical-care costs of
$110,520 (95% CI: 110,324-110,739). PCa-related costs
($34,432, 95% CI: 34,359-34,507) made up approximately
31% of total medical-care costs. Total medical costs ran-
ged from $73,587-$120,085 (Stage I: $120,085, 95% CI:
119,819-120,357; Stage II: $113,616, 95% CI: 113,174-
114,067; Stage III: $110,943, 95% CI: 110,525-111,412;
Stage IV: $73,587, 95% CI: 73,142-74,029). Stage IV total
costs ($73,587) were lower reflecting shorter periods of
survival compared to patients diagnosed at lower stages.
PCa-related lifetime costs were highest for Stage I
($39,182, 95% CI: 39,075-39,292), followed by Stage II
($31,915, 95% CI: 31,769-32,063), Stage IV ($30,038, 95%
CI: 29,824-30,244), and Stage III ($26,078, 95% CI: 25,975-
26,189). However, after adjusting PCa costs by length of
follow-up, per year costs for Stage IV ($8,118) were much
higher relative to Stages I ($2,740), II ($2,128), and III
($1,590), reflecting higher medical resource use intensity
characteristic of distant stage patients.
Aggregate life-time total costs for all incident cases ≥
65 years and diagnosed in the U.S. during 2008 were
$12.4 billion. Aggregate costs associated with PCa-
related medical care totaled approximately $3.9 billion.
Discussion
Prostate cancer places a significant burden on the U.S.
Medicare system with average per-patient life-time attri-
butable costs of approximately $34,000 (discounted at
3%). PCa-related costs represented approximately one-
third of total medical care costs. Our analyses indicate
that the aggregate life-time disease-related burden attri-
butable to incident PCa cases ≥ 65 years of age in 2008
approaches $4.0B (discounted at 3%). PCa-related life-
time costs were variable by cancer stage and ranged from
$26,078 (Stage III) to $39,182 (Stage I). Stage IV had the
poorest prognosis as the mean survival time was only 44
months compared to 172, 180, and 196 months for
Stages I, II, and III, respectively.
A study conducted by Riley and colleagues examined
total life-time costs of several cancers including prostate
in elderly Medicare-eligible patients using the SEER-
Medicare database [14]. To the best of our knowledge
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time estimates of treatment costs. Riley et al. estimated
costs in PCa patients ≥ 65 years of age using data from
1984 to 1990, an era pre-dating widespread use of the
PSA screening test [14]. Comparison of our dataset with
Riley et al. allows us to examine trends in survival and
costs occurring over time. We report estimates of total
life-time costs that are higher (Stages I, II: $118,261,
Stage III: $110,943, Stage IV: $73,587) relative to Riley
(Local: $98,447; Regional: $99,542; Distant: $62,634,
adjusted to 2004 US$). We also estimate longer periods
of survival (13.2 vs. Riley: 7.0 years). This finding is lar-
g e l yt h er e s u l to ft h ef a c tt h a tt h em a j o r i t yo fP C a
patients diagnosed in the era of widespread PSA screen-
ing that has taken place since the early 1990s are now
diagnosed at earlier stages and no longer have excess
mortality compared to the general population [9]. Upon
adjusting total costs by year of follow-up, our estimates
were actually lower ($8,373) relative to Riley et al.
($13,028, adjusted to 2004 US$) [14]. This finding may
suggest that PCa patients can now expect to have lower
morbidity related to earlier diagnosis and therefore also
accrue fewer costs. Patients diagnosed at earlier stages
may also be more likely to receive watchful waiting
which has the effect of lowering costs relative to patients
diagnosed at higher stages.
Table 2 Demographic and Clinical Characteristics (SEER-Medicare, incident PCa cases ≥ 65 years old diagnosed during
1991-2002)
Characteristic Stage I Stage II Stage III Stage IV All
N, % 71,861 51.1% 25,590 18.2% 22,103 15.7% 21,011 14.9% 140,565 100.0%
Age at study index
Mean (SD) 73.8 (5.8) 72.9 (5.8) 71.3 (5.3) 75.30 (7.2) 73.5 (6.1)
Median 73 72 70 74 73
Age (5-year categories), N, %:
65-69 18,974 26.4% 8,715 34.1% 9,738 44.1% 5,424 25.8% 42,851 30.5%
70-74 22,922 31.9% 7,844 30.7% 7,378 33.4% 5,401 25.7% 43,545 31.0%
75-79 18,140 25.2% 5,486 21.4% 3,230 14.6% 4,349 20.7% 31,205 22.2%
80-84 8,235 11.5% 2,428 9.5% 1,177 5.3% 3,261 15.5% 15,101 10.7%
85+ 3,590 5.0% 1,117 4.4% 580 2.6% 2,576 12.3% 7,863 5.6%
Race, N, %:
White 58,410 81.3% 20,674 80.8% 18,327 82.9% 15,873 75.6% 113,284 80.6%
Black 7,448 10.4% 2,661 10.4% 1,839 8.3% 2,935 14.0% 14,883 10.6%
Asian 2,572 3.6% 916 3.6% 807 3.7% 861 4.1% 5,073 3.6%
Other 3,431 4.7% 1,339 5.2% 1,130 5.1% 1,342 6.3% 7,325 5.2%
Geographic region, N, %:
Midwest 14,040 19.5% 4,531 17.7% 4,216 19.1% 4,357 20.7% 27,144 19.3%
Northeast 12,303 17.1% 3,416 13.4% 2,041 9.2% 2,426 11.6% 20,186 14.4%
South 7,024 9.8% 2,362 9.2% 1,566 7.1% 1,588 7.6% 12,540 8.9%
West 38,494 53.6% 15,281 59.7% 14,280 64.6% 12,640 60.2% 80,695 57.4%
Predicted mean survival time (SD) in months 172 (85.9) 180.1 (95.8) 196.3 (107.0) 43.7 (39.1) 158.2 (99.2)
Mean survival time (SD) in months
Initial 5.8 (1.1) 5.8 (1.1) 5.8 (1.1) 4.4 (2.5) 5.6 (1.5)
Continuing 154.9 (85.0) 162.9 (95.1) 179.2 (106.2) 29.2 (36.5) 141.4 (98.0)
Terminal 11.8 (1.2) 11.8 (1.1) 11.8 (1.7) 10.6 (3.1) 11.6 (1.7)
N = Number of patients, SD = Standard deviation, SEER = Surveillance, Epidemiology, and End Results
Table 3 Mean Life-time Costs and Survival, by Cancer Stage (US$ 2004)*
Study Measure Stage I Stage II Stage III Stage IV All Patients
Number of patients 71,861 25,590 22,103 21,011 140,565
Total costs $120,085 $113,616 $110,943 $73,587 $110,520
PCa-related costs $39,182 $31,915 $26,078 $30,038 $34,432
Average years of survival 14.3 15.0 16.4 3.7 13.2
Total costs per year $8,398 $7,574 $6,765 $19,888 $8,373
PCa-related costs per year $2,740 $2,128 $1,590 $8,118 $2,608
*Costs discounted at 3%
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PCa patients were diagnosed approximately 3.4 years
younger compared to Stages I/II (age at diagnosis: 67.8
vs. 71.2 years). Prior studies examining treatment and
survival outcomes using SEER registry data and data
from a tumor registry in Germany have also similarly
reported that Stage III patients are diagnosed at younger
ages versus Stages I/II [15,16]. As part of our analysis, we
a s s u m e dt h a ts u r v i v a la m o n gS t a g eI - I I IP C ap a t i e n t s
would follow the U.S. general population based in part
on 5-year relative survival statistics from SEER reporting
that PCa patients diagnosed with local and regional dis-
ease is 100% [3]. Relative survival is a measure of net sur-
vival that is calculated by comparing overall survival with
survival from similar individuals without cancer. We con-
sidered this to be a conservative assumption with respect
to our estimation of costs since prior studies have
reported relative survival for local/regional stage PCa in
excess of 100% [9,16]. This finding may be explained in
part by the fact that many local/regional stage tumors are
diagnosed as a result of PSA screening and men who
undergo this preventive measure may in fact be healthier
compared to men who do not participate in PSA testing
[17]. Therefore, when we estimated predicted mean sur-
vival for Stage I-III patients based on U.S. life tables,
longer survival for Stage III versus Stage I/II patients was
a function of their earlier mean age at PCa diagnosis as
well as the assumption that survival for these patients
would follow the U.S. general population. Rather than
report age-adjusted survival estimates, the authors con-
sidered it important to have the survival data reflect the
finding that Stage III patients are diagnosed at earlier
ages relative to Stages I/II.
This study was subject to several limitations. Since PCa
patients generally have a good prognosis following diag-
nosis and therefore long survival times, we did not have
information on the date of death for the majority of
patients in SEER. This was especially problematic for
patients diagnosed at Stages I-III where it was assumed
survival for these patients would follow the U.S. general
population. This was a conservative assumption as a
prior study reported relative survival rates for early stage
PCa that were greater than 100% [9].
In partitioning the survival periods of patients into dis-
tinct phases of care, we used methodology similar to a
study conducted by Brown and colleagues [7,11]. It should
be noted that these studies were conducted in populations
of colorectal, breast and lung cancer patients. However,
we believe that the application of their methodology to
PCa is appropriate despite the fact that many early stage
patients may receive watchful waiting. In a prior study, we
found that ~45% of Stage I patients received active therapy
[12]. It may be argued that, for Stage I-IIa patients where a
watchful waiting approach is more common, separate
initial and continuing care phases may not have been war-
ranted. However, in defining treatment phases we also
looked at diagnostic procedures for cancer staging as well
as outpatient visits and hospitalizations and, in our
exploratory analyses, we found that more early stage PCa
patients used these service types in the first 6 months fol-
lowing cancer diagnosis. Therefore, we considered sepa-
rate initial and continuing care phases appropriate for
early stage PCa. Furthermore, our analyses of healthcare
costs for each treatment phase among Stage I patients
showed a U-shaped pattern characteristic of patients uti-
lizing a higher degree of medical services both in the
months shortly following PCa diagnosis and in the months
leading up to death compared to the months defined as
continuing care.
The economic analysis was conducted from a payer
perspective and includes reimbursement payments made
to physicians, facilities and other healthcare professionals
for the medical services that were provided to PCa
patients. Other components of the economic burden of
PCa including out-of-pocket spending on direct medical
care as well as the indirect costs associated with reduced
productivity and lost work time for both caregivers and
patients were not included in this study. These cost com-
ponents have been shown to represent an important pro-
portion of the total cost burden. A study by Chang and
colleagues reported monthly costs of $373, $698, and
$302 for absenteeism, short-term disability, and deducti-
bles/copayments, respectively among newly diagnosed
cancer (including brain, colorectal, lung, ovarian, pan-
creatic, prostate, and non-Hodgkin’s lymphoma) patients
during the first few years following cancer diagnosis [18].
Absenteeism and short-term disability data were not
available in the data sources used for the current analysis.
However, this may not have contributed greatly to costs
related to PCa as the population was ≥ 65 years old and
not likely to have still been working. It should also be
n o t e dt h a tM e d i c a r ec o s td a t af r o mc a l e n d a ry e a r s1 9 9 1
through 2004 were used for this current study. During
this time, Medicare did not cover most prescription
drugs. Hence, prescription drug costs were not included
in our estimates of direct medical costs.
It is also important to note that our survival estimates
for Stage IV patients do not account for the index year of
PCa diagnosis in order to adjust for improvements in
prognosis among patients diagnosed in more recent years.
A recent study reports that during the early 1990s until
2001, the 5-year relative survival of Stage IV patients has
increased from approximately 50%-60% [19]. Therefore,
this will have the effect of underestimating slightly the
economic burden of PCa for recently diagnosed Stage IV
patients.
Finally, it should be noted that the estimation of life-
time costs is an area of research that is highly speculative
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and cost profiles of a cohort of patients diagnosed during
calendar years 1991 through 2005. It is unlikely that the
resource trends and costs of patients diagnosed in 2008
and more recently will exactly mirror the experience of
past cohorts. For example, laproscopic and robot-assisted
surgical methods are now currently more widely used.
Advances have also been made in the treatment of
advanced stage PCa. In 2004, it was shown that docetaxel
can prolong survival in men with advanced PCa no
longer responding to hormone therapy and in 2010,
cabazitaxel was approved for use in advanced PCa after
failure with docetaxel. As a result of these treatment
advances, the PCa cost estimates reported in this study
will probably understate slightly the initial and life-time
treatment costs for PCa patients diagnosed today.
Conclusions
Our analyses offer insight into the magnitude of total
and disease-related lifetime costs for patients ≥ 65 years
of age at PCa diagnosis in an era of improved screening
and treatment (1991-2002). Long-term estimates are
useful for understanding the upper limit of treatment
costs that could be avoided should prevention strategies
prove effective in reducing incident PCa cases. Study
results indicate that the aggregate lifetime PCa-related
burden for 2008 incident cases ≥ 65 years old is
approximately $4.0 billion.
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